MYOTONIC DYSTROPHY TYPE 1 (DM1)
Clinical trials for MYOTONIC DYSTROPHY TYPE 1 (DM1) explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY TYPE 1 (DM1) trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vertex tests long-term safety of VX-670 for muscle disease
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects a…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Hope for muscle strength: new drug targets myotonic dystrophy
Disease control OngoingThis phase 3 trial tests an experimental drug called AOC 1001 in 159 adults with myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. Participants receive either the drug or a placebo by intravenous infusion. The main goal is to see if the dru…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC